scPharmaceuticals (SCPH) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: 107.79%
• EPS Growth: -16.01%
• Country: US
• Employees: N/A
• Sector: N/A
• Sector Strength: N/A
• Industry: N/A
• EPS (TTM): N/A
• Shares Outstanding: N/A
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: $6.00

scPharmaceuticals' overall stock score is primarily impacted by its financial instability, with high debt levels and negative cash flows posing significant risks. However, strong technical indicators and positive strategic developments, such as the merger with MannKind Corporation, provide a counterbalance, suggesting potential for future growth. The earnings call further supports optimism with robust revenue growth and strategic advancements, despite ongoing cost challenges.

scPharmaceuticals Business Overview & Revenue Model

Company Description

How the Company Makes Money

scPharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products, particularly Furoscix, once it receives regulatory approval. The company's revenue model includes direct sales of its products to healthcare providers and patients. Additionally, scPharmaceuticals may engage in partnerships and collaborations with other pharmaceutical companies or healthcare organizations, which can provide upfront payments, milestone payments, and royalties based on product sales. These strategic partnerships can enhance the company's financial stability and expand its market reach. The company may also explore licensing agreements that allow other entities to develop or market its products, further contributing to its revenue streams.

scPharmaceuticals Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

scPharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: ―
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCPH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 5.64, equal to the 50-day MA of 5.34, and equal to the 200-day MA of 3.86, indicating a bullish trend. The MACD of 0.10 indicates Positive momentum. The RSI at 64.40 is Neutral, neither overbought nor oversold. The STOCH value of 66.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCPH.

scPharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―

scPharmaceuticals Corporate Events

scPharmaceuticals Announces Merger with MannKind Corporation

On August 24, 2025, scPharmaceuticals entered into a merger agreement with MannKind Corporation, which will acquire all outstanding shares of scPharmaceuticals through a tender offer. The acquisition, valued at up to $360 million, aims to diversify and accelerate MannKind’s revenue growth, particularly with FUROSCIX, and strengthen its position in the cardiometabolic and lung disease sectors. The merger is expected to close in the fourth quarter of 2025, subject to regulatory approvals and customary conditions. This strategic move is anticipated to enhance MannKind’s market reach and integrate scPharmaceuticals’ commercial capabilities into its existing infrastructure.

scPharmaceuticals Extends SmartDose Supply Agreement

On August 20, 2025, scPharmaceuticals Inc. amended its supply agreement with West Pharmaceutical Services, Inc. for the SmartDose® drug delivery system, extending the agreement’s term until December 31, 2027. The amendment outlines the company’s financial responsibilities upon termination, impacting its operational commitments and strategic partnerships in the drug delivery market.

scPharmaceuticals Holds Annual Stockholders Meeting June 2025

On June 3, 2025, scPharmaceuticals Inc. held its Annual Meeting of Stockholders, with 35,156,523 shares represented, accounting for approximately 69.91% of the company’s outstanding common stock. During the meeting, William T. Abraham, M.D., Mette Kirstine Agger, and Minnie Baylor-Henry were elected as Class II Directors, and the appointment of RSM US LLP as the independent registered public accounting firm was ratified. Additionally, the compensation of the company’s named executive officers was approved on an advisory basis.